Last reviewed · How we verify
LY3841136
At a glance
| Generic name | LY3841136 |
|---|---|
| Also known as | Eloralintide |
| Sponsor | Eli Lilly and Company |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight (PHASE2)
- Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight (PHASE3)
- A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes (PHASE3)
- A Study of Eloralintide (LY3841136) in Participants With Obstructive Sleep Apnea and Obesity or Overweight (PHASE3)
- A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin (PHASE3)
- A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes (PHASE3)
- A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. (PHASE1)
- A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- LY3841136 CI brief — competitive landscape report
- LY3841136 updates RSS · CI watch RSS
- Eli Lilly and Company portfolio CI